# IN8bio, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/IN8bio, Inc). ## Overview IN8bio, Inc. is a clinical-stage biotechnology company developing genetically modified gamma-delta T cell therapies for cancer. The company is focused on advancing its lead program INB-100 and earlier-stage pipeline assets, while relying on external financing and collaborations to fund development. ## Products & services • INB-100 clinical-stage gamma-delta T cell therapy • INB-400 preclinical cell therapy program • INB-619 earlier-stage pipeline asset • INB-633 earlier-stage pipeline asset • Allogeneic and autologous engineered T cell platforms • Collaboration/licensing opportunities for pipeline assets - **Clinical-stage cell therapy** (45%) — Lead therapeutic candidates in human development, centered on INB-100 for cancer. - **Preclinical pipeline** (35%) — Earlier-stage programs being advanced through discovery and preclinical work, including INB-400. - **Platform and manufacturing capabilities** (15%) — Genetically modified gamma-delta T cell technology, manufacturing processes, and supporting know-how. - **Licensing and collaboration rights** (5%) — Potential partnering, licensing, and other third-party arrangements around pipeline assets. - INB-100 clinical-stage gamma-delta T cell therapy - INB-400 preclinical cell therapy program - INB-619 earlier-stage pipeline asset - INB-633 earlier-stage pipeline asset - Allogeneic and autologous engineered T cell platforms - Collaboration/licensing opportunities for pipeline assets ## Customers IN8bio does not yet sell commercial products, so its near-term counterparties are clinical investigators, hospitals, contract research organizations, and contract manufacturing organizations that support development. If approved, its therapies would be sold to oncology treatment centers and administered by specialized healthcare professionals for cancer patients. The company also seeks strategic partners for selected programs to help fund development and broaden commercialization options. - **Clinical trial sites and investigators** (primary) — They run studies for INB-100 and other candidates, enabling patient enrollment, data generation, and regulatory progress. - **Contract research and manufacturing organizations** (primary) — They provide preclinical, clinical, and manufacturing services needed to advance the pipeline without in-house scale. - **Oncology treatment centers** (secondary) — These would be the commercial delivery points for approved cell therapies, where specialist physicians administer treatment. - **Strategic collaboration partners** (secondary) — Biopharma partners may license or co-develop assets such as INB-400 and earlier-stage programs to share cost and risk. - Cancer patients treated through oncology centers if products are approved - Hospitals and specialist physicians involved in cell therapy administration - Clinical trial sites and investigators running INB-100 studies - CROs and CMOs that support development and manufacturing - Potential pharma or biotech partners for licensing and collaboration ## Geography IN8bio is headquartered in New York and currently concentrates its development and planned commercialization efforts in the United States. The company has not disclosed meaningful country revenue because it has not generated product revenue, and its business remains pre-commercial. Its operating model depends on U.S.-based research, clinical development, and regulatory execution, with potential selective partnerships in other markets later. - Headquartered in New York, United States - Primary development and planned commercialization focus is the U.S. - No product revenue disclosed; company remains pre-commercial - Clinical and manufacturing partners may be used domestically and abroad - Future non-U.S. partnering could expand reach without heavy infrastructure ## Strategy The company’s near-term strategy is to advance INB-100, progress preclinical assets, and strengthen internal R&D capabilities while preserving cash. It is also actively seeking funding and partnerships for INB-400 and earlier-stage programs, using collaborations and licensing to extend runway and reduce capital intensity. - **Advance INB-100 clinical development** (short-term) — The lead program is the main value driver and the most advanced asset in the pipeline. - **Partner or license earlier-stage assets** (short-term) — Collaborations can fund development and reduce the company’s capital burden. - **Preserve liquidity and extend runway** (short-term) — The company has disclosed substantial doubt about going concern without additional financing. - **Build internal R&D and commercialization capability** (medium-term) — A stronger internal platform improves execution if programs reach later-stage development or approval. - Advance INB-100 through clinical development - Progress preclinical pipeline assets toward key milestones - Seek partners for INB-400 and earlier-stage programs - Raise capital through equity, debt, ATM, or private placements - Preserve cash by prioritizing programs and reducing near-term spend ## Risks IN8bio is a pre-revenue biotech with substantial going-concern risk, so its ability to continue operations depends on raising capital and/or securing partnerships. Its pipeline also depends on clinical success, regulatory approval, and reliable third-party manufacturing and IP access, all of which are common failure points in cell therapy development. - **Insufficient liquidity and going-concern uncertainty** [critical] — Cash is not expected to fund operations beyond the disclosed runway without new capital. - **Clinical trial and regulatory failure** [high] — Pipeline value depends on successful human data and regulatory clearance for cell therapies. - **Single-source supplier dependence** [high] — Critical manufacturing inputs such as automated manufacturing devices and lentiviral vectors come from a single third-party supplier. - **Intellectual property and license compliance** [high] — The company depends on third-party licenses; breach or loss of rights could block development and commercialization. - **Cybersecurity and data privacy incidents** [medium] — R&D, clinical, and vendor data are sensitive and exposed to ransomware, supply-chain, and remote-work threats. - **Key-person dependence** [medium] — The company is highly dependent on its co-founders and scientific leadership for execution. - Going-concern risk if financing is not raised in time - Clinical development risk for INB-100 and other pipeline assets - Dependence on single-source suppliers for critical manufacturing inputs - Heavy reliance on licensed intellectual property and compliance with agreements - Cybersecurity and data privacy risks from sensitive R&D and trial data - Key-person risk tied to founders and scientific leadership ## Accounting As a pre-revenue biotech, the main accounting focus is on cash runway, financing transactions, and the valuation of equity-linked instruments rather than revenue recognition. R&D spending, stock-based compensation, lease accounting, and warrant/placement accounting can materially affect reported losses and liquidity presentation. The company also must assess going-concern disclosures and any impairment or fair-value issues tied to financing instruments and intangible rights. - **Going-concern assessment** — Affects financial statement presentation and investor assessment of survival risk - **Equity financing and warrant accounting** — Affects cash, shareholders' equity, and dilution analysis - **Research and development expense recognition** — Drives operating loss and quarterly volatility - **Stock-based compensation** — Inflates operating expenses and affects comparability - **Lease accounting** — Affects cash flow classification and liabilities - No product revenue yet, so results are driven by R&D and financing items - Stock-based compensation can materially affect operating expense - ATM, private placement, and warrant accounting affect equity and cash flow - Lease accounting affects liabilities and financing cash outflows - Going-concern disclosure is central to financial statement interpretation --- *Last updated: 2026-09-24T10:46:58.300559+00:00*